Nexpro

Nexpro may be available in the countries listed below.

Ingredient matches for Nexpro

Esomeprazole

Esomeprazole is reported as an ingredient of Nexpro in the following countries:

• Bangladesh


• India

Esomeprazole magnesium, trihydrate (a derivative of Esomeprazole) is reported as an ingredient of Nexpro in the following countries:

• Myanmar

International Drug Name Search

Trimexole-F

Trimexole-F may be available in the countries listed below.

Ingredient matches for Trimexole-F

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Trimexole-F in the following countries:

• Mexico

Trimethoprim

Trimethoprim is reported as an ingredient of Trimexole-F in the following countries:

• Mexico

International Drug Name Search

Enalapril / HCT ratiopharm

Enalapril/HCT ratiopharm may be available in the countries listed below.

Ingredient matches for Enalapril/HCT ratiopharm

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalapril/HCT ratiopharm in the following countries:

• Austria

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Enalapril/HCT ratiopharm in the following countries:

• Austria

International Drug Name Search

Altacef

Altacef may be available in the countries listed below.

Ingredient matches for Altacef

Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Altacef in the following countries:

• Ecuador


• Myanmar

International Drug Name Search

Dexamedron

Dexamedron may be available in the countries listed below.

Ingredient matches for Dexamedron

Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexamedron in the following countries:

• Myanmar

International Drug Name Search

Timol

Timol may be available in the countries listed below.

Ingredient matches for Timol

Timolol

Timolol maleate (a derivative of Timolol) is reported as an ingredient of Timol in the following countries:

• Sri Lanka

International Drug Name Search

Tiamol

Tiamol may be available in the countries listed below.

Ingredient matches for Tiamol

Fluocinonide

Fluocinonide is reported as an ingredient of Tiamol in the following countries:

• Canada

International Drug Name Search

Otriven Baby Phenylephrin

Otriven Baby Phenylephrin may be available in the countries listed below.

Ingredient matches for Otriven Baby Phenylephrin

Phenylephrine

Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Otriven Baby Phenylephrin in the following countries:

• Germany

International Drug Name Search

Porodron

Porodron may be available in the countries listed below.

Ingredient matches for Porodron

Alendronic Acid

Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Porodron in the following countries:

• Italy

International Drug Name Search

Papaverine HCl ratiopharm

Papaverine HCl ratiopharm may be available in the countries listed below.

Ingredient matches for Papaverine HCl ratiopharm

Papaverine

Papaverine hydrochloride (a derivative of Papaverine) is reported as an ingredient of Papaverine HCl ratiopharm in the following countries:

• Netherlands

International Drug Name Search

Quinupristine

Quinupristine may be available in the countries listed below.

Ingredient matches for Quinupristine

Quinupristin

Quinupristine (DCF) is known as Quinupristin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Antiopiaz

Antiopiaz may be available in the countries listed below.

Ingredient matches for Antiopiaz

Naloxone

Naloxone hydrochloride (a derivative of Naloxone) is reported as an ingredient of Antiopiaz in the following countries:

• Argentina

International Drug Name Search

Taro-Carbamazepine

Taro-Carbamazepine may be available in the countries listed below.

Ingredient matches for Taro-Carbamazepine

Carbamazepine

Carbamazepine is reported as an ingredient of Taro-Carbamazepine in the following countries:

• Canada

International Drug Name Search

GenRX Frusemide

GenRX Frusemide may be available in the countries listed below.

Ingredient matches for GenRX Frusemide

Furosemide

Furosemide is reported as an ingredient of GenRX Frusemide in the following countries:

• Australia

International Drug Name Search

Ropivacaine Hydrochloride

Ropivacaine Hydrochloride may be available in the countries listed below.

Ingredient matches for Ropivacaine Hydrochloride

Ropivacaine

Ropivacaine Hydrochloride (BANM) is known as Ropivacaine in the US.

International Drug Name Search

Glossary

BANM	British Approved Name (Modified)

Click for further information on drug naming conventions and International Nonproprietary Names.

Spiriva

Spiriva is a brand name of tiotropium, approved by the FDA in the following formulation(s):

SPIRIVA (tiotropium bromide monohydrate - powder; inhalation)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: January 30, 2004
  
  Strength(s): EQ 0.018MG BASE/INH ^[RLD]

Has a generic version of Spiriva been approved?

No. There is currently no therapeutically equivalent version of Spiriva available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spiriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Powders for inhalation
  Patent 5,478,578
  Issued: December 26, 1995
  Inventor(s): Arnold; Klaus & Grass; Peter & Knecht; Adolf & Roos; Robert & Sluke; Gerhard & Thieme; Herbet & Wenzel; Joachim
  Assignee(s): Boehringer Ingelheim KG
  In order to control and optimize the amount of inhalable active substance released when drugs are administered as inhalation powders, the invention calls for the use of auxiliaries consisting of mixtures of coarser particles (average particle size>20 .mu.m) and finer particles (average particle size
  
  Patent expiration dates:
  
  
  • December 26, 2012
    
    ✓ 
    Drug product
  
  



• 
  Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
  Patent 6,777,423
  Issued: August 17, 2004
  Inventor(s): Rolf; Banholzer & Peter; Sieger & Christian; Kulinna & Michael; Trunk & Manfred; Graulich & Peter; Specht & Helmut; Meissner & Andreas; Mathes
  Assignee(s): Boehringer Ingelheim Pharma KG
  Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
  
  Patent expiration dates:
  
  
  • September 24, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
  Patent 6,908,928
  Issued: June 21, 2005
  Inventor(s): Banholzer; Rolf & Sieger; Peter & Kulinna; Christian & Trunk; Michael & Graulich; Manfred & Specht; Peter & Meissner; Helmut & Mathes; Andreas
  Assignee(s): BI Pharma KG.
  Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
  
  Patent expiration dates:
  
  
  • September 24, 2021
    
    ✓ 
    Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 24, 2021
    
    ✓ 
    Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Inhalable powder containing tiotropium
  Patent 7,070,800
  Issued: July 4, 2006
  Inventor(s): Bechtold-Peters; Karoline & Walz; Michael & Boeck; Georg & Doerr; Rolf
  Assignee(s): Boehringer Ingelheim Pharma KG
  The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
  
  Patent expiration dates:
  
  
  • January 22, 2022
    
    ✓ 
    Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
    ✓ 
    Drug product
  
  



• 
  Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
  Patent 7,309,707
  Issued: December 18, 2007
  Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
  Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
  The invention relates to a crystalline micronisate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
  
  Patent expiration dates:
  
  
  • September 24, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
  Patent 7,642,268
  Issued: January 5, 2010
  Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
  Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
  The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
  
  Patent expiration dates:
  
  
  • September 24, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Dry powder inhaler
  Patent 7,694,676
  Issued: April 13, 2010
  Inventor(s): Wachtel; Herbert
  Assignee(s): Boehringer Ingelheim GmbH
  An inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint; and an actuating member which can be moved out a resting position and thereby interacts with at least one pin which can be made to pierce the capsule holder.
  
  Patent expiration dates:
  
  
  • March 12, 2027
    
    ✓ 
    Drug product
  
  



• 
  Method for the administration of an anticholinergic by inhalation
  Patent 8,022,082
  Issued: September 20, 2011
  Inventor(s): Zierenberg; Bernd
  Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
  An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L containing the inhalable powder.
  
  Patent expiration dates:
  
  
  • January 19, 2026
    
    ✓ 
    Patent use: ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
    ✓ 
    Drug product
  
  



• 
  Process for preparing powder formulations
  Patent RE38912
  Issued: December 6, 2005
  Inventor(s): Walz; Michael & Boeck; Georg
  Assignee(s): Boehringer Ingelheim Pharma KG
  The invention relates to a new process for producing powdered preparations for inhalation.
  
  Patent expiration dates:
  
  
  • October 11, 2021
    
    ✓ 
    Drug product
  
  



• 
  Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
  Patent RE39820
  Issued: September 4, 2007
  Inventor(s): Banholzer; Rolf & Bauer; Rudolf & Reichl; Richard
  Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
  Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3α-(6β, 7β-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3α-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3β-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3α-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
  
  Patent expiration dates:
  
  
  • January 30, 2018
    
    ✓ 
    Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 17, 2012 - PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
  
  

See also...

• Spiriva Consumer Information (Drugs.com)
• Spiriva HandiHaler Consumer Information (Wolters Kluwer)
• Spiriva Consumer Information (Cerner Multum)
• Spiriva Advanced Consumer Information (Micromedex)
• Spiriva Handihaler AHFS DI Monographs (ASHP)
• Tiotropium Consumer Information (Wolters Kluwer)
• Tiotropium inhalation Consumer Information (Cerner Multum)
• Tiotropium Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Tiotropium Bromide AHFS DI Monographs (ASHP)

Hyprolose

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0009004-64-2

Therapeutic Categories

Pharmaceutic aid

Dermatological agent: Skin protectant

Chemical Name

Cellulose 2-hydroxypropyl ether (IUPAC, WHO)

Foreign Names

• Hyprolosum (Latin)
• Hydroxypropyl cellulose (German)
• Hyprolose (French)
• Hiprolosa (Spanish)

Generic Names

• Hydroxypropylcellulose (OS: DCF, JAN)
• E 463 (IS)
• Hydroxypropyl Cellulose (IS: NF)
• Hydroxypropyl Cellulose (PH: USP 30)
• Hydroxypropylcellulose (PH: BP 2010, Ph. Franç. Xe édit, Ph. Eur. 6)
• Hydroxypropylcellulose, Low-Substituted (PH: USP 30, JP XIV)
• Hydroxypropylcellulosum (PH: Ph. Int. 4, Ph. Eur. 6)
• Idrossipropilcellulosa (PH: F.U. VIII)

Brand Names

• A-Gel
  Pharmatel Fresenius Kabi NZ Ltd, New Zealand



• Lacrisert
  Aton, United States; Merck Frosst, Canada; Merck Sharp & Dohme, France; Merck Sharp & Dohme, Netherlands; Merck Sharp & Dohme, Taiwan; MSD, Finland

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
NF	The National Formulary (USA)
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Octrim

Octrim may be available in the countries listed below.

Ingredient matches for Octrim

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Octrim in the following countries:

• Bangladesh

Trimethoprim

Trimethoprim is reported as an ingredient of Octrim in the following countries:

• Bangladesh

International Drug Name Search